- Home
- WHF vs AQST Comparison
WHF vs AQST Comparison
Compare WHF & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- AQST
- Stock Information
- Founded
- WHF 2011
- AQST 2004
- Country
- WHF United States
- AQST United States
- Employees
- WHF N/A
- AQST N/A
- Industry
- WHF Finance Companies
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- AQST Health Care
- Exchange
- WHF Nasdaq
- AQST Nasdaq
- Market Cap
- WHF 229.4M
- AQST 274.4M
- IPO Year
- WHF 2012
- AQST 2018
- Fundamental
- Price
- WHF $9.82
- AQST $2.64
- Analyst Decision
- WHF Sell
- AQST Strong Buy
- Analyst Count
- WHF 4
- AQST 7
- Target Price
- WHF $10.83
- AQST $10.57
- AVG Volume (30 Days)
- WHF 84.6K
- AQST 2.2M
- Earning Date
- WHF 03-07-2025
- AQST 03-05-2025
- Dividend Yield
- WHF 15.71%
- AQST N/A
- EPS Growth
- WHF N/A
- AQST N/A
- EPS
- WHF 0.47
- AQST N/A
- Revenue
- WHF $92,817,000.00
- AQST $57,561,000.00
- Revenue This Year
- WHF N/A
- AQST N/A
- Revenue Next Year
- WHF N/A
- AQST $35.72
- P/E Ratio
- WHF $20.99
- AQST N/A
- Revenue Growth
- WHF N/A
- AQST 13.80
- 52 Week Low
- WHF $9.45
- AQST $2.24
- 52 Week High
- WHF $13.44
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- WHF 29.15
- AQST 40.08
- Support Level
- WHF $10.16
- AQST $2.45
- Resistance Level
- WHF $11.31
- AQST $2.85
- Average True Range (ATR)
- WHF 0.28
- AQST 0.20
- MACD
- WHF -0.15
- AQST -0.02
- Stochastic Oscillator
- WHF 6.87
- AQST 25.00
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate attractive risk-adjusted returns for investors, primarily by originating senior secured loans to privately held small-cap companies across a broad range of industries.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.